Yankelevitz David F, Yip Rowena, Smith James P, Liang Mingzhu, Liu Ying, Xu Dong Ming, Salvatore Mary M, Wolf Andrea S, Flores Raja M, Henschke Claudia I
From the Departments of Radiology (D.F.Y., R.Y., M.L., Y.L., D.M.X., M.M.S., C.I.H.) and Thoracic Surgery (A.S.W., R.M.F.), Icahn School of Medicine at Mount Sinai, 1 Gustave Levy Pl, New York, NY 10029; Department of Medicine, Weill Cornell Medical College, New York, NY (J.P.S.); Department of Radiology, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China (M.L.); Department of Diagnostic Radiology, Cancer Hospital Chinese Academy of Medical Sciences & National Cancer Center of China, Beijing, China (Y.L.).
Radiology. 2015 Nov;277(2):555-64. doi: 10.1148/radiol.2015142554. Epub 2015 Jun 23.
To address the frequency of identifying nonsolid nodules, diagnosing lung cancer manifesting as such nodules, and the long-term outcome after treatment in a prospective cohort, the International Early Lung Cancer Action Program.
A total of 57,496 participants underwent baseline and subsequent annual repeat computed tomographic (CT) screenings according to an institutional review board, HIPAA-compliant protocol. Informed consent was obtained. The frequency of participants with nonsolid nodules, the course of the nodule at follow-up, and the resulting diagnoses of lung cancer, treatment, and outcome are given separately for baseline and annual repeat rounds of screening. The χ(2) statistic was used to compare percentages.
A nonsolid nodule was identified in 2392 (4.2%) of 57,496 baseline screenings, and pathologic pursuit led to the diagnosis of 73 cases of adenocarcinoma. A new nonsolid nodule was identified in 485 (0.7%) of 64,677 annual repeat screenings, and 11 had a diagnosis of stage I adenocarcinoma; none were in nodules 15 mm or larger in diameter. Nonsolid nodules resolved or decreased more frequently in annual repeat than in baseline rounds (322 [66%] of 485 vs 628 [26%] of 2392, P < .0001). Treatment of the cases of lung cancer was with lobectomy in 55, bilobectomy in two, sublobar resection in 26, and radiation therapy in one. Median time to treatment was 19 months (interquartile range [IQR], 6-41 months). A solid component had developed in 22 cases prior to treatment (median transition time from nonsolid to part-solid, 25 months). The lung cancer-survival rate was 100% with median follow-up since diagnosis of 78 months (IQR, 45-122 months).
Nonsolid nodules of any size can be safely followed with CT at 12-month intervals to assess transition to part-solid. Surgery was 100% curative in all cases, regardless of the time to treatment.
在一项前瞻性队列研究——国际早期肺癌行动计划中,探讨非实性结节的检出频率、诊断表现为此类结节的肺癌情况以及治疗后的长期预后。
根据机构审查委员会批准的、符合健康保险流通与责任法案(HIPAA)的方案,共有57496名参与者接受了基线及随后每年的重复计算机断层扫描(CT)筛查。已获得知情同意书。分别给出基线筛查和年度重复筛查中出现非实性结节的参与者频率、随访时结节的变化过程以及最终肺癌诊断、治疗和预后情况。采用χ²检验比较百分比。
在57496次基线筛查中有2392例(4.2%)发现非实性结节,经病理追踪诊断出73例腺癌。在64677次年度重复筛查中有485例(0.7%)发现新的非实性结节,其中11例诊断为Ⅰ期腺癌;直径15mm或更大的结节中无一例为腺癌。年度重复筛查中非实性结节消退或缩小的频率高于基线筛查(485例中的322例[66%]对比2392例中的628例[26%],P <.0001)。肺癌病例的治疗方式为肺叶切除术55例、双肺叶切除术2例、亚肺叶切除术26例、放射治疗1例。治疗的中位时间为19个月(四分位间距[IQR],6 - 41个月)。22例在治疗前出现了实性成分(从非实性转变为部分实性的中位时间为25个月)。自诊断以来的中位随访时间为78个月(IQR,45 - 122个月),肺癌生存率为100%。
任何大小的非实性结节均可安全地每隔12个月进行CT随访以评估向部分实性的转变。无论治疗时间如何,所有病例手术治愈率均为100%。